Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine

Vaccine

Volumn 26, Issue 36, 2008, Pages 4647-4654

  Rodriguez, Pedro C ^a   Gonzalez, Ileana ^a   Gonzalez, Adys ^a   Avellanet, Janet ^a   Lopez, Armando ^a   Perez, Rolando ^a   Lage, Agustin ^a   Montero, Enrique ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Boosting; EGF; Priming

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL PROTEIN; CANCER VACCINE; CARRIER PROTEIN; CYTOKINE ANTIBODY; EPITOPE; MONTANIDE ISA 51; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; DRUG EFFECT; FEMALE; IMMUNOPHARMACOLOGY; LOW DRUG DOSE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEOPLASM; BACTERIAL OUTER MEMBRANE PROTEINS; CANCER VACCINES; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MANNITOL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLEIC ACIDS;

EID: 48849094983     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.003     Document Type: Article

References (66)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 2 (2008) 71-96
2. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
3. Ward S., Copier J., and Dalgleish A. Technical challenges facing therapeutic cancer vaccines. Curr Opin Drug Discov Devel 11 2 (2008) 168-177
4. Reichert J.M., and Wenger J.B. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 13 1-2 (2008) 30-37
5. Mocellin S., Mandruzzato S., Bronte V., and Marincola F.M. Cancer vaccines: pessimism in check. Nat Med 10 12 (2004) 1278-1279 [Author reply 79-80]
6. Montero E., Amador J.F., Perez R., and Lage A. Tumor-specific immunotherapy based on dominant models of natural tolerance. Med Hypotheses 54 4 (2000) 531-536
7. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 9 (2004) 909-915
8. Pardoll D.M. Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A 96 10 (1999) 5340-5342
9. Aucouturier J, Ascarateil S, Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine 2006; 24 Suppl 2:S2-44-5.
10. Ahonen C.L., Wasiuk A., Fuse S., Turk M.J., Ernstoff M.S., Suriawinata A.A., et al. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 111 6 (2008) 3116-3125
11. Berd D., Sato T., Maguire Jr. H.C., Kairys J., and Mastrangelo M.J. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22 3 (2004) 403-415
12. Lage A., Perez R., and Fernandez L.E. Therapeutic cancer vaccines: at midway between immunology and pharmacology. Curr Cancer Drug Targets 5 8 (2005) 611-627
13. Garcia B., Neninger E., de la Torre A., Leonard I., Martinez R., Viada C., et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 14 3 (2008) 840-846
14. Gonzalez G., and Lage A. Cancer vaccines for hormone/growth factor immune deprivation: a feasible approach for cancer treatment. Curr Cancer Drug Targets 7 3 (2007) 229-241
15. Gonzalez G., Crombet T., Catala M., Mirabal V., Hernandez J.C., Gonzalez Y., et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 9 4 (1998) 431-435
16. Gonzalez G., Pardo O.L., Sanchez B., Garcia J.L., Beausoleil I., Marinello P., et al. Induction of immune recognition of self-epidermal growth factor II: characterization of the antibody immune response and the use of a fusion protein. Vac Res 6 2 (1997) 91-100
17. Gonzalez G., Sanchez B., Suarez E., Beausoleil I., Perez O., Lastre M., et al. Induction of immune recognition of self-epidermal growth factor (EGF): effect on EGF biodistribution and tumor growth. Vac Res 5 4 (1996) 233-244
18. Gonzalez G., Crombet T., Torres F., Catala M., Alfonso L., Osorio M., et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 14 3 (2003) 461-466
19. Gonzalez G., Crombet T., Neninger E., Viada C., and Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vac 3 1 (2007) 8-13
20. Zinkernagel R.M., Ehl S., Aichele P., Oehen S., Kundig T., and Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 156 (1997) 199-209
21. Friedman A., and Cohen I.R. T cell Ir phenotype modified by excising primary antigen deposit. Immunogenetics 19 5 (1984) 449-454
22. Zinkernagel R.M., and Hengartner H. Regulation of the immune response by antigen. Science 293 5528 (2001) 251-253
23. Starzl T.E., and Zinkernagel R.M. Antigen localization and migration in immunity and tolerance. N Engl J Med 339 26 (1998) 1905-1913
24. Gardiner D.F., Huang Y., Basu S., Leung L., Song Y., Chen Z., et al. Multiple-site DNA vaccination enhances immune responses in mice. Vaccine 24 3 (2006) 287-292
25. Nicholson K.G., Prestage H., Cole P.J., Turner G.S., and Bauer S.P. Multisite intradermal antirabies vaccination. Immune responses in man and protection of rabbits against death from street virus by postexposure administration of human diploid-cell-strain rabies vaccine. Lancet 2 8252 (1981) 915-918
26. Khawplod P., Wilde H., Tepsumethanon S., Limusanno S., Tantawichien T., Chomchey P., et al. Prospective immunogenicity study of multiple intradermal injections of rabies vaccine in an effort to obtain an early immune response without the use of immunoglobulin. Clin Infect Dis 35 12 (2002) 1562-1565
27. Warrell M.J., Suntharasamai P., Nicholson K.G., Warrell D.A., Chanthavanich P., Viravan C., et al. Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens. Lancet 1 8382 (1984) 874-876
28. Dennehy M., and Williamson A.L. Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine 23 10 (2005) 1209-1224
29. Jansen T., Hofmans M.P., Theelen M.J., Manders F.G., and Schijns V.E. Dose and timing requirements for immunogenicity of viral poultry vaccine antigen: investigations of emulsion-based depot function. Avian Pathol 36 5 (2007) 361-365
30. Couch M., Saunders J.K., O'Malley Jr. B.W., Pardoll D., and Jaffee E. Spatial distribution of tumor vaccine improves efficacy. Laryngoscope 113 8 (2003) 1401-1405
31. Atanackovic D., Altorki N.K., Cao Y., Ritter E., Ferrara C.A., Ritter G., et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A 105 5 (2008) 1650-1655
32. Mitchison N.A. T-cell-B-cell cooperation. Nat Rev Immunol 4 4 (2004) 308-312
33. Gonzalez G., Montero E., Leon K., Cohen I.R., and Lage A. Autoimmunization to epidermal growth factor, a component of the immunological homunculus. Autoimmun Rev 1 1-2 (2002) 89-95
34. Harris R.C., Chung E., and Coffey R.J. EGF receptor ligands. Exp Cell Res 284 1 (2003) 2-13
35. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56 (1987) 881-914
36. Gregory H. Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature 257 5524 (1975) 325-327
37. Savage Jr. C.R., Hash J.H., and Cohen S. Epidermal growth factor. Location of disulfide bonds. J Biol Chem 248 22 (1973) 7669-7672
38. Raaberg L., Nexo E., Jorgensen P.E., Poulsen S.S., and Jakab M. Fetal effects of epidermal growth factor deficiency induced in rats by autoantibodies against epidermal growth factor. Pediatr Res 37 2 (1995) 175-181
39. Raaberg L., Nexo E., Poulsen S.S., and Jorgensen P.E. An immunologic approach to induction of epidermal growth factor deficiency: induction and characterization of autoantibodies to epidermal growth factor in rats. Pediatr Res 37 2 (1995) 169-174
40. Rajewsky K., Schirrmacher V., Nase S., and Jerne N.K. The requirement of more than one antigenic determinant for immunogenicity. J Exp Med 129 6 (1969) 1131-1143
41. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110 6 (2002) 775-787
42. Gourley T.S., Wherry E.J., Masopust D., and Ahmed R. Generation and maintenance of immunological memory. Semin Immunol 16 5 (2004) 323-333
43. Ochsenbein A.F., Pinschewer D.D., Sierro S., Horvath E., Hengartner H., and Zinkernagel R.M. Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. Proc Natl Acad Sci U S A 97 24 (2000) 13263-13268
44. Wrammert J., and Ahmed R. Maintenance of serological memory. Biol Chem 389 5 (2008) 537-539
45. Gonzalez S., Nazabal C., Rao K.V., Reyes O., Garay H.E., Caballero E., et al. Cell mediated immune response elicited in mice after immunization with the P64k meningococcal protein: epitope mapping. FEMS Immunol Med Microbiol 42 2 (2004) 233-239
46. Gonzalez S., Vina L., Nazabal C., Chinea G., Caballero E., and Musacchio A. B-cell epitope mapping of the Neisseria meningitidis P64k protein using overlapping peptides. Biotechnol Appl Biochem 32 Pt 1 (2000) 1-8
47. Gonzalez S., Alvarez A., Caballero E., Vina L., Guillen G., and Silva R. P64k meningococcal protein as immunological carrier for weak immunogens. Scand J Immunol 52 2 (2000) 113-116
48. Goidl E.A., Paul W.E., Siskind G.W., and Benacerraf B. The effect of antigen dose and time after immunization on the amount and affinity of anti-hapten antibody. J Immunol 100 2 (1968) 371-375
49. Manz R.A., Thiel A., and Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 388 6638 (1997) 133-134
50. Slifka M.K., Antia R., Whitmire J.K., and Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 8 3 (1998) 363-372
51. Manz R.A., Hauser A.E., Hiepe F., and Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 23 (2005) 367-386
52. Roth R., Gee R.J., and Mamula M.J. B lymphocytes as autoantigen-presenting cells in the amplification of autoimmunity. Ann N Y Acad Sci 815 (1997) 88-104
53. Leclerc C., Sedlik C., Lo-Man R., Charlot B., Rojas M., and Deriaud E. Stimulation of a memory B cell response does not require primed helper T cells. Eur J Immunol 25 9 (1995) 2533-2538
54. Bernasconi N.L., Traggiai E., and Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298 5601 (2002) 2199-2202
55. Mitchison N.A. Induction of immunological paralysis in two zones of dosage. Proc R Soc Lond B Biol Sci 161 (1964) 275-292
56. Warrell M.J., Riddell A., Yu L.M., Phipps J., Diggle L., Bourhy H., et al. A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods. PLoS Negl Trop Dis 2 4 (2008) e224
57. Bronte V., Wang M., Overwijk W.W., Surman D.R., Pericle F., Rosenberg S.A., et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol 161 10 (1998) 5313-5320
58. Franceschi C., Valensin S., Fagnoni F., Barbi C., and Bonafe M. Biomarkers of immunosenescence within an evolutionary perspective: the challenge of heterogeneity and the role of antigenic load. Exp Gerontol 34 8 (1999) 911-921
59. Grossi C.E., Ciccone E., Tacchetti C., Santoro G., and Anastasi G. Anatomy of the immune system: facts and problems. Ital J Anat Embryol 105 4 (2000) 97-124
60. Zinkernagel R.M. Localization dose and time of antigens determine immune reactivity. Semin Immunol 12 3 (2000) 163-171 [Discussion 257-344]
61. Monsurro V., Nielsen M.B., Perez-Diez A., Dudley M.E., Wang E., Rosenberg S.A., et al. Kinetics of TCR use in response to repeated epitope-specific immunization. J Immunol 166 9 (2001) 5817-5825
62. Powell Jr. D.J., and Rosenberg S.A. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother 27 1 (2004) 36-47
63. Kaml M., Weiskirchner I., Keller M., Luft T., Hoster E., Hasford J., et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine 24 47-48 (2006) 6808-6811
64. Civin C.I., Levine H.B., Williamson A.R., and Schlossman S.F. The effects of antigen dose and adjuvant on the antibody response; amplification of restricted B cell clones. J Immunol 116 5 (1976) 1400-1406
65. Sela M. Antigenicity: some molecular aspects. Science 166 911 (1969) 1365-1374
66. Deshmukh U.S., Lewis J.E., Gaskin F., Kannapell C.C., Waters S.T., Lou Y.H., et al. Immune responses to Ro60 and its peptides in mice. I. The nature of the immunogen and endogenous autoantigen determine the specificities of the induced autoantibodies. J Exp Med 189 3 (1999) 531-540